Literature DB >> 15973077

Prognostic significance of p53 overexpression after hepatic resection of hepatocellular carcinoma.

Chang Okh Sung1, Byung Chul Yoo, Kwang Cheol Koh, Jae-Won Cho, Cheol Keun Park.   

Abstract

BACKGROUND/AIMS: p53 mutation is the most common genetic abnormality in human cancers. However, although it has been reported that p53 overexpression in hepatocellular carcinoma (HCC) is associated with the aggressive behavior of tumor, the prognostic significance of p53 overexpression in HCC remains controversial. The aims of the present study were to examine the correlations between p53 overexpression and the clinicopathologic parameters of HCCs, and to determine the prognostic significance of p53 overexpression in HCC.
METHODS: Immunohistochemical analysis of p53 overexpression was performed in 105 consecutive cases of HCC who underwent curative hepatic resection. Survival curves were calculated using the Kaplan-Meier method and multivariate analysis of outcome predictors for HCCs was assessed by logistic regression analysis.
RESULTS: p53 overexpression was observed in 20 of 105 HCCs (19.0%). Multivariate analysis identified significant correlations between p53 overexpression and microvascular invasion (p=0.027), liver cirrhosis (p=0.035), 1-year survival rate (p=0.016), multiple tumors (p=0.014), and the presence of tumor capsule (p=0.010). The 2-year survival rate was poorer in patients without tumor capsule (p=0.043).
CONCLUSIONS: Our results show a positive association between p53 overexpression and microvascular invasion in HCC, and indicate that p53 overexpression is a poor prognostic factor of survival, especially within 1 year after liver resection in HCC patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15973077

Source DB:  PubMed          Journal:  Korean J Gastroenterol        ISSN: 1598-9992


  8 in total

Review 1.  Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival.

Authors:  Zhao-Shan Niu; Xiao-Jun Niu; Mei Wang
Journal:  World J Hepatol       Date:  2015-01-27

2.  Prognostic significance of c-Met, β-catenin and FAK in patients with hepatocellular carcinoma following surgery.

Authors:  Xue-Yi Gong; Ning Ma; Hong-Xu Xu; Fan Chen; Xiao-Hui Huang; Qian Wang
Journal:  Oncol Lett       Date:  2018-01-05       Impact factor: 2.967

3.  TP53 immunohistochemical expression is associated with the poor outcome for hepatocellular carcinoma: evidence from a meta-analysis.

Authors:  Ya-nan Ji; Qin Wang; Jun Xue
Journal:  Tumour Biol       Date:  2014-02

Review 4.  Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a systematic review and meta-analysis.

Authors:  Jiangbo Liu; Qingyong Ma; Min Zhang; Xinshuai Wang; Dong Zhang; Wei Li; Fengfei Wang; Erxi Wu
Journal:  Eur J Cancer       Date:  2012-03-27       Impact factor: 9.162

5.  Correlation between expression of p53, p21/WAF1, and MDM2 proteins and their prognostic significance in primary hepatocellular carcinoma.

Authors:  Mei-Fang Zhang; Zhi-Yi Zhang; Jia Fu; Yu-Feng Yang; Jing-Ping Yun
Journal:  J Transl Med       Date:  2009-12-22       Impact factor: 5.531

6.  Prognostic significance of TP53 expression for patients with hepatocellular carcinoma: a meta-analysis.

Authors:  Ping Zhan; Ya-Nan Ji
Journal:  Hepatobiliary Surg Nutr       Date:  2014-02       Impact factor: 7.293

7.  The transcriptomic G1-G6 signature of hepatocellular carcinoma in an Asian population: Association of G3 with microvascular invasion.

Authors:  John Carson Allen; Jean-Charles Nault; Guili Zhu; Andrew Yu Keat Khor; Jin Liu; Tony Kiat Hon Lim; Jessica Zucman-Rossi; Pierce K H Chow
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

8.  Prognostic significance of p53, mTOR, c-Met, IGF-1R, and HSP70 overexpression after the resection of hepatocellular carcinoma.

Authors:  Gu Hyum Kang; Byung Seok Lee; Eaum Seok Lee; Seok Hyun Kim; Heon Young Lee; Dae Young Kang
Journal:  Gut Liver       Date:  2014-01-13       Impact factor: 4.519

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.